BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizos CV, Liberopoulos EN, Tellis CC, Florentin M, Elisaf MS, Tselepis AD. Combining Rosuvastatin with Sartans of Different Peroxisome Proliferator-Activated Receptor-γ Activating Capacity Is Not Associated with Different Changes in Low-Density Lipoprotein Subfractions and Plasma Lipoprotein-Associated Phospholipase A 2. Metabolic Syndrome and Related Disorders 2011;9:217-23. [DOI: 10.1089/met.2010.0120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Rizos CV, Kostapanos MS, Rizos EC, Tselepis AD, Elisaf MS. The Effect of Rosuvastatin on Low-Density Lipoprotein Subfractions in Patients With Impaired Fasting Glucose. J Cardiovasc Pharmacol Ther 2015;20:276-83. [DOI: 10.1177/1074248414549419] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
2 Filippatos TD, Elisaf MS. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opin Pharmacother. 2011;12:1945-1958. [PMID: 21736529 DOI: 10.1517/14656566.2011.593509] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
3 Rizos CV, Liberopoulos EN, Tellis K, Dinicolantonio JJ, Tselepis AD, Elisaf MS. Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPARγ-Activating Capacity: Effects on High-Density Lipoprotein Subfractions and Associated Enzymes. Angiology 2015;66:36-42. [DOI: 10.1177/0003319713512556] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]